The company had reported net loss of Rs 6.511.16 crore in the second quarter due to impairment charges. Meanwhile, huge spending on infrastructure pushed up steel prices, benefitting steelmakers. However, higher coking coal costs have weighed on the gains.

Read More

​ The company had reported net loss of Rs 6.511.16 crore in the second quarter due to impairment charges. Meanwhile, huge spending on infrastructure pushed up steel prices, benefitting steelmakers. However, higher coking coal costs have weighed on the gains. The company had reported net loss of Rs 6.511.16 crore in the second quarter due to impairment charges. Meanwhile, huge spending on infrastructure pushed up steel prices, benefitting steelmakers. However, higher coking coal costs have weighed on the gains.  Moneycontrol Latest News Read More  

The company had reported net loss of Rs 6.511.16 crore in the second quarter due to impairment charges. Meanwhile, huge spending on infrastructure pushed up steel prices, benefitting steelmakers. However, higher coking coal costs have weighed on the gains.

The price band for the offer has been fixed at Rs 186-Rs 192 per share.

Read More

​ The price band for the offer has been fixed at Rs 186-Rs 192 per share. The price band for the offer has been fixed at Rs 186-Rs 192 per share.  Moneycontrol Latest News Read More  

The price band for the offer has been fixed at Rs 186-Rs 192 per share.

KR Choksey is bullish on Kotak Mahindra Bank has recommended buy rating on the stock with a target price of Rs 2150 in its research report dated January 24, 2024.

Read More

​ KR Choksey is bullish on Kotak Mahindra Bank has recommended buy rating on the stock with a target price of Rs 2150 in its research report dated January 24, 2024. KR Choksey is bullish on Kotak Mahindra Bank has recommended buy rating on the stock with a target price of Rs 2150 in its research report dated January 24, 2024.  Moneycontrol Latest News Read More  

KR Choksey is bullish on Kotak Mahindra Bank has recommended buy rating on the stock with a target price of Rs 2150 in its research report dated January 24, 2024.

KR Choksey recommended accumulate rating on UltraTech Cement with a target price of Rs 10,286 in its research report dated January 24, 2024.

Read More

​ KR Choksey recommended accumulate rating on UltraTech Cement with a target price of Rs 10,286 in its research report dated January 24, 2024. KR Choksey recommended accumulate rating on UltraTech Cement with a target price of Rs 10,286 in its research report dated January 24, 2024.  Moneycontrol Latest News Read More  

KR Choksey recommended accumulate rating on UltraTech Cement with a target price of Rs 10,286 in its research report dated January 24, 2024.

KR Choksey recommended hold rating on Colgate-Palmolive (India) with a target price of Rs 2548 in its research report dated January 23, 2024.

Read More

​ KR Choksey recommended hold rating on Colgate-Palmolive (India) with a target price of Rs 2548 in its research report dated January 23, 2024. KR Choksey recommended hold rating on Colgate-Palmolive (India) with a target price of Rs 2548 in its research report dated January 23, 2024.  Moneycontrol Latest News Read More  

KR Choksey recommended hold rating on Colgate-Palmolive (India) with a target price of Rs 2548 in its research report dated January 23, 2024.

KR Choksey recommended accumulate rating on Hindustan Unilever with a target price of Rs 2716 in its research report dated January 23, 2024.

Read More

​ KR Choksey recommended accumulate rating on Hindustan Unilever with a target price of Rs 2716 in its research report dated January 23, 2024. KR Choksey recommended accumulate rating on Hindustan Unilever with a target price of Rs 2716 in its research report dated January 23, 2024.  Moneycontrol Latest News Read More  

KR Choksey recommended accumulate rating on Hindustan Unilever with a target price of Rs 2716 in its research report dated January 23, 2024.

KR Choksey recommended accumulate rating on Tatva Chintan Pharma Chem with a target price of Rs 1487 in its research report dated January 24, 2024.

Read More

​ KR Choksey recommended accumulate rating on Tatva Chintan Pharma Chem with a target price of Rs 1487 in its research report dated January 24, 2024. KR Choksey recommended accumulate rating on Tatva Chintan Pharma Chem with a target price of Rs 1487 in its research report dated January 24, 2024.  Moneycontrol Latest News Read More  

KR Choksey recommended accumulate rating on Tatva Chintan Pharma Chem with a target price of Rs 1487 in its research report dated January 24, 2024.

Entero Healthcare Solutions IPO has received observation letter from the market regulator on January 16, while the SEBI issued the said letter to Exicom Tele-Systems IPO, and Stallion India Fluorochemicals IPO on January 19

Read More

​ Entero Healthcare Solutions IPO has received observation letter from the market regulator on January 16, while the SEBI issued the said letter to Exicom Tele-Systems IPO, and Stallion India Fluorochemicals IPO on January 19 Entero Healthcare Solutions IPO has received observation letter from the market regulator on January 16, while the SEBI issued the said letter to Exicom Tele-Systems IPO, and Stallion India Fluorochemicals IPO on January 19  Moneycontrol Latest News Read More  

Entero Healthcare Solutions IPO has received observation letter from the market regulator on January 16, while the SEBI issued the said letter to Exicom Tele-Systems IPO, and Stallion India Fluorochemicals IPO on January 19

As per the government notification, the eligible exchanges are the India International Exchange and NSE International Exchange.

Read More

​ As per the government notification, the eligible exchanges are the India International Exchange and NSE International Exchange. As per the government notification, the eligible exchanges are the India International Exchange and NSE International Exchange.  Moneycontrol Latest News Read More  

As per the government notification, the eligible exchanges are the India International Exchange and NSE International Exchange.

More than 90% of all companies are family companies and a third of companies in SP 500 index have a family element. Yet thanks to a combination of demographics and changing social mores, many family firms now face the ultimate threat to their survival: a shortage of heirs. The best family firms are not just engines of progress and innovation, but are repositories of public trust

Read More

​ More than 90% of all companies are family companies and a third of companies in SP 500 index have a family element. Yet thanks to a combination of demographics and changing social mores, many family firms now face the ultimate threat to their survival: a shortage of heirs. The best family firms are not just engines of progress and innovation, but are repositories of public trust More than 90% of all companies are family companies and a third of companies in SP 500 index have a family element. Yet thanks to a combination of demographics and changing social mores, many family firms now face the ultimate threat to their survival: a shortage of heirs. The best family firms are not just engines of progress and innovation, but are repositories of public trust  Moneycontrol Latest News Read More  

More than 90% of all companies are family companies and a third of companies in SP 500 index have a family element. Yet thanks to a combination of demographics and changing social mores, many family firms now face the ultimate threat to their survival: a shortage of heirs. The best family firms are not just engines of progress and innovation, but are repositories of public trust